Imaging the Effects of Netarsudil (Rhopressa) on the Trabecular Meshwork in Glaucoma and Ocular Hypertension

Part of paid clinical trials in Bloomington, Indiana.

Sponsor
Indiana University
Study ID
NCT07588152
Phase
PHASE4
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Netarsudil Ophthalmic Solution (Rhopressa) — DRUG
    Netarsudil ophthalmic solution is an FDA-approved Rho kinase inhibitor indicated for the treatment of ocular hypertension and open-angle glaucoma. In this study, it will be administered once daily in the evening for approximately 14 days.
  • Artificial Tears (AT) — OTHER
    Artificial tears will be used as a placebo control and administered once daily in the evening for approximately 14 days. These drops are not expected to lower intraocular pressure or alter trabecular meshwork structure.

Study Details

This study evaluates the effects of netarsudil (Rhopressa) on the trabecular meshwork in subjects with ocular hypertension or open-angle glaucoma. Participants will be randomized to receive either netarsudil or placebo (artificial tears). High-resolution imaging using adaptive optics gonioscopy, anterior segment optical coherence tomography (AS-OCT), and OCT gonioscopy will be performed at baseline and after approximately 14 days of treatment. The primary objective is to assess changes in trabecular meshwork lamellae spacing, with secondary measures including trabecular meshwork height, width, and Schlemm's canal diameter.

Key Dates

Start date
Jun 5, 2026
Status verified
Jun 2026
Primary completion
Jun 30, 2028
Completion
Jun 30, 2028

Study Design

Enrollment
50 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Active Comparator: Netarsudil (Rhopressa)
    Participants will receive netarsudil ophthalmic solution administered as one drop in the study eye once daily in the evening for approximately 14 days.
  • Placebo Comparator: Placebo (Artificial Tears)
    Participants will receive artificial tears administered as one drop in the study eye once daily in the evening for approximately 14 days.

Primary Outcome Measure

Change in Trabecular Meshwork Lamellae Spacing [ Time Frame: Baseline to 14-21 days after initiation of treatment ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Indiana Universtiy School of OptometryBloomingtonIndiana47405-

Find similar trials in Bloomington, IN

By condition
Glaucoma
By specialty
Ophthalmology
By research site
Indiana Universtiy School of Optometry· Bloomington, IN

Related Studies